These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 33128316

  • 21. First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.
    Pavlick AC, Zhao R, Lee CH, Ritchings C, Rao S.
    Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
    [Abstract] [Full Text] [Related]

  • 22. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [Abstract] [Full Text] [Related]

  • 23. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Klee G, Kurzhals J, Hagelstein V, Zillikens D, Recke A, Langan EA, Terheyden P.
    Melanoma Res; 2021 Oct 01; 31(5):464-471. PubMed ID: 34284462
    [Abstract] [Full Text] [Related]

  • 24. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
    Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, Isei T, Takenouchi T, Kato H, Mizuhashi S, Fukushima S, Yamamoto Y, Inozume T, Fujisawa Y, Yamasaki O, Nakamura Y, Asai J, Maekawa T, Funakoshi T, Matsushita S, Nakano E, Oashi K, Kato J, Uhara H, Miyagawa T, Uchi H, Hatta N, Tsutsui K, Maeda T, Matsuya T, Yanagisawa H, Muto I, Okumura M, Ogata D, Yamazaki N.
    Cancer Med; 2023 Sep 01; 12(17):17967-17980. PubMed ID: 37584204
    [Abstract] [Full Text] [Related]

  • 25. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
    Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA.
    Cancer Immunol Res; 2021 Oct 01; 9(10):1202-1213. PubMed ID: 34389558
    [Abstract] [Full Text] [Related]

  • 26. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
    Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.
    Cancer Immunol Immunother; 2019 May 01; 68(5):765-772. PubMed ID: 30806748
    [Abstract] [Full Text] [Related]

  • 27. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA.
    J Immunother Cancer; 2021 Oct 01; 9(10):. PubMed ID: 34625515
    [Abstract] [Full Text] [Related]

  • 30. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
    Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.
    N Engl J Med; 2015 May 21; 372(21):2006-17. PubMed ID: 25891304
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C, Tian J, Liu H, Li F, Niu H, Zhu B.
    Medicine (Baltimore); 2017 Jun 21; 96(26):e7325. PubMed ID: 28658143
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
    Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA.
    J Immunother Cancer; 2019 Mar 29; 7(1):89. PubMed ID: 30922394
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
    Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G.
    J Immunother Cancer; 2022 Jul 29; 10(7):. PubMed ID: 35798536
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T.
    JAMA Dermatol; 2020 Sep 01; 156(9):982-986. PubMed ID: 32667663
    [Abstract] [Full Text] [Related]

  • 39. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
    Prescrire Int; 2016 Dec 01; 25(177):289-292. PubMed ID: 30758924
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.